Definition and epidemiology
Depersonalization-derealization disorder is a dissociative disorder defined by persistent or recurrent episodes of depersonalization (feeling detached from oneself, observing oneself from outside) and/or derealization (feeling that the external world is unreal, dreamlike, or distorted). By DSM-5 criteria, symptoms must cause clinically significant distress or functional impairment, and reality testing must remain intact.
The lifetime prevalence is approximately 1-2% in the general population, making it the third most common psychiatric symptom after anxiety and depression. Transient depersonalization or derealization experiences are much more common, occurring in up to 50% of adults at some point, particularly during acute stress or trauma. Chronic DDD typically begins in adolescence or early adulthood, with mean age of onset around 16 years. There is no clear gender predominance, though some studies suggest slightly higher rates in women. The disorder is often chronic, with waxing and waning symptoms, though some patients experience continuous symptoms.
- DDD is characterized by persistent detachment from self or surroundings WITH intact reality testing—patients know it is not real.
- Depersonalization = detachment from self; derealization = detachment from surroundings; both can coexist in DDD.
- Distinguish from psychosis: in DDD reality testing is preserved; in psychosis it is impaired—patient believes experiences are real.
- Often triggered by severe stress, trauma, or substance use (especially cannabis); typically begins in adolescence or early adulthood.
- Neuroimaging shows decreased limbic activity with increased prefrontal activity—excessive inhibition of emotional processing.
- First-line treatment is CBT with grounding techniques; no FDA-approved medications; SSRIs treat comorbid anxiety/depression.
- Lamotrigine is considered for cases refractory to CBT after 3-6 months, especially when depression is absent; avoid benzodiazepines (may worsen dissociation).
- Comorbid anxiety and depression are very common (up to 70% and 60% respectively); address these with therapy and SSRIs/SNRIs.
Etiology and risk factors
The etiology of DDD is multifactorial, involving biological, psychological, and environmental factors.
Risk factors include:
- Childhood trauma or abuse: emotional neglect and emotional abuse are particularly strong predictors
- Severe acute stress: traumatic events, life-threatening situations, or overwhelming psychological stress
- Anxiety disorders: particularly panic disorder, generalized anxiety disorder, and social anxiety disorder
- Substance use: especially cannabis, hallucinogens, ketamine, and MDMA
- Neurobiological factors: alterations in prefrontal cortex activity, limbic system dysfunction, and hypothalamic-pituitary-adrenal axis dysregulation
- Family history: possible genetic vulnerability, though specific genes have not been identified
- Sleep deprivation: chronic poor sleep quality
- Migraine: higher comorbidity with migraine headaches
The disorder is conceptualized as a defense mechanism—emotional numbing in response to overwhelming stress or trauma. Neuroimaging studies suggest hypoactivation of limbic structures (amygdala, insula) responsible for emotional processing, with compensatory hyperactivation of prefrontal regions involved in emotional regulation.
Pathophysiology
The pathophysiology of DDD involves disruption of normal integrated processing of self-awareness, emotional experience, and sensory perception.
Neurobiological mechanisms
Corticolimbic dysfunction: Neuroimaging studies demonstrate decreased activity in the anterior insula and amygdala (emotional processing centers) with increased activity in prefrontal cortex regions, particularly ventrolateral prefrontal cortex. This pattern suggests excessive top-down inhibition of emotional processing.
HPA axis alterations: Some studies show blunted cortisol responses to stress, suggesting chronic HPA axis dysregulation similar to patterns seen in PTSD.
Neurotransmitter systems: Abnormalities in multiple neurotransmitter systems are implicated, including serotonin, glutamate (particularly NMDA receptor function), and endogenous opioid systems.
Psychological mechanisms
The leading psychological model posits DDD as a protective dissociative response to overwhelming emotional experiences. When emotional arousal exceeds the individual's capacity to cope, the brain essentially "disconnects" emotional and sensory processing from conscious awareness. This creates the subjective experience of detachment but preserves reality testing, unlike psychotic disorders where reality testing is impaired.
The disorder may be maintained by hypervigilance to internal dissociative sensations and catastrophic misinterpretation of these experiences, creating anxiety that perpetuates the cycle.
Clinical features
Patients with DDD describe characteristic experiences of detachment that are often difficult to articulate.
Depersonalization symptoms
- Feeling detached from one's body, thoughts, or emotions
- Observing oneself from outside (out-of-body experiences)
- Feeling like an automaton or robot
- Emotional numbness—feeling unable to experience emotions normally
- Body distortions—feeling that body parts are changed in size or shape
- Distorted sense of time (time moving very slowly or quickly)
Derealization symptoms
- Surroundings feel unreal, dreamlike, or foggy
- Visual distortions—objects appear flat, two-dimensional, or altered in size
- Sounds seem distant or distorted
- Familiar places feel unfamiliar
- Feeling as if living in a movie or behind glass
Associated features
- Intact reality testing: patients recognize their experiences as distortions, not actual reality (critical distinguishing feature)
- Anxiety: often severe, particularly health anxiety focused on fear of "going crazy" or losing control
- Depression: comorbid major depressive disorder is common
- Rumination: obsessive focus on the dissociative experiences
- Cognitive complaints: difficulty concentrating, memory problems (subjective, typically not evident on objective testing)
Symptoms may be continuous or episodic. Episodes can be triggered by stress, anxiety, fatigue, overstimulation, or substance use. Some patients experience brief episodes lasting minutes to hours, while others have persistent symptoms for years.
Diagnosis
Diagnosis is clinical, based on history and mental status examination. There are no specific laboratory or imaging tests for DDD.
DSM-5 diagnostic criteria
- Persistent or recurrent depersonalization, derealization, or both
- Reality testing remains intact (patient knows the experiences are not real)
- Symptoms cause clinically significant distress or functional impairment
- Not attributable to substance use, another medical condition, or better explained by another mental disorder
Clinical evaluation
History: Detailed psychiatric history focusing on onset, duration, frequency, triggers, and impact on functioning. Screen for trauma history, substance use, and comorbid psychiatric conditions.
Mental status examination: Patients typically appear anxious but are fully oriented with organized thought processes. Reality testing is intact—they can clearly articulate that their experiences feel unreal but acknowledge they are experiencing distortions, not actual changes in reality. This distinguishes DDD from psychotic disorders.
Screening instruments: The Cambridge Depersonalization Scale is a validated questionnaire that can help quantify symptom severity.
Medical workup
Rule out medical and substance-related causes:
- Neurological evaluation: if symptoms are atypical or accompanied by neurological signs, consider brain MRI to exclude structural lesions, temporal lobe epilepsy, or migraine-related phenomena
- Thyroid function tests: hypothyroidism or hyperthyroidism can produce dissociative symptoms
- Toxicology screen: cannabis, hallucinogens, dissociative anesthetics
- Sleep study: if significant sleep disturbance is present
Differential considerations
Document absence of hallucinations, delusions, thought disorder, and confirm insight into the unreal nature of experiences.
Differential diagnosis
Multiple conditions can present with dissociative symptoms or feelings of unreality.
| Condition | Distinguishing features |
|---|---|
| Panic disorder | Depersonalization/derealization occur during panic attacks, episodic and brief (typically < 1 hour), accompanied by acute autonomic symptoms |
| Schizophrenia/psychotic disorders | Impaired reality testing, presence of hallucinations or delusions, patient believes experiences are real |
| Substance intoxication | Temporal relationship to substance use (cannabis, hallucinogens, ketamine, alcohol), resolves with abstinence |
| Temporal lobe epilepsy | Brief stereotyped episodes (seconds to minutes), often with other epileptic features, abnormal EEG |
| Post-traumatic stress disorder | Dissociation occurs in context of trauma reminders, accompanied by intrusive memories, avoidance, hyperarousal |
| Major depressive disorder | Emotional blunting is pervasive mood symptom, not discrete detachment experiences, responds to antidepressants |
| Generalized anxiety disorder | Worry-focused rather than dissociation-focused, no descriptions of detachment from self/surroundings |
| Migraine | Dissociative symptoms occur with or just before headache, brief duration, accompanied by other migraine features |
| Hypothyroidism | Fatigue, weight gain, cold intolerance, elevated TSH |
| Brain tumor/structural lesion | Progressive course, neurological signs, abnormal imaging |
The key distinguishing feature of DDD is that dissociative experiences are the primary complaint, are persistent or recurrent over time, and occur with preserved insight (intact reality testing).
Management
Treatment of DDD is challenging, as the disorder is often chronic and refractory. Evidence is limited, with most data from case series and small trials.
Psychotherapy (first-line)
Cognitive behavioral therapy is the best-studied and most effective treatment. Key components include:
- Psychoeducation: explaining the disorder reduces catastrophic interpretations and anxiety
- Grounding techniques: sensory-based interventions to reconnect with present reality (e.g., 5-4-3-2-1 technique, holding ice, focused breathing)
- Cognitive restructuring: challenging catastrophic thoughts about dissociative symptoms
- Anxiety management: addressing comorbid anxiety that perpetuates dissociation
- Exposure: gradual confrontation of avoided situations that trigger dissociation
Trauma-focused therapy: for patients with trauma history, addressing underlying trauma through trauma-focused CBT or EMDR (eye movement desensitization and reprocessing) may be beneficial.
Acceptance-based approaches: mindfulness and acceptance strategies to reduce struggle with dissociative experiences.
Pharmacotherapy
No medications are FDA-approved specifically for DDD, and evidence for pharmacological treatment is weak. Medications target comorbid conditions or are used off-label based on limited data.
SSRIs/SNRIs: First choice when comorbid depression or anxiety is present. May reduce associated anxiety but often have limited direct effect on depersonalization/derealization. Examples include fluoxetine, sertraline, escitalopram, venlafaxine.
Lamotrigine: Some open-label studies and case reports suggest benefit, possibly through glutamate modulation. Considered for patients refractory to first-line psychotherapy after 3-6 months, especially when significant depression is absent.
Clomipramine: Older tricyclic antidepressant with some case report support.
Naltrexone: Opioid antagonist with theoretical rationale based on endogenous opioid hypothesis; very limited evidence.
Avoid benzodiazepines: Generally not recommended despite anxiety; may worsen dissociation and carry dependence risk.
Avoid antipsychotics: Not indicated unless comorbid psychotic disorder; no evidence of benefit in DDD.
Lifestyle interventions
- Sleep hygiene: ensuring adequate, regular sleep
- Stress management: regular exercise, relaxation techniques
- Substance avoidance: complete abstinence from cannabis, alcohol, and other dissociogenic substances
- Limiting rumination: reducing excessive focus on dissociative symptoms
Treatment approach
Start with psychoeducation and CBT-based psychotherapy. Add an SSRI or SNRI if significant comorbid anxiety or depression is present. For refractory cases not responding to first-line psychotherapy after 3-6 months, especially when depression is minimal or absent, consider a lamotrigine trial. Long-term follow-up is important, as the disorder is often chronic.
Complications and prognosis
Complications
- Functional impairment: difficulty with work, school, or social relationships due to concentration problems and emotional detachment
- Comorbid psychiatric disorders: high rates of major depressive disorder (up to 60%), anxiety disorders (up to 70%), and other dissociative disorders
- Substance use disorders: patients may self-medicate with alcohol or other substances, potentially worsening dissociation
- Suicidal ideation: present in up to 50% of patients, typically driven by comorbid depression and feelings of hopelessness about chronic symptoms
- Social withdrawal: isolation due to difficulty relating to others and fear of stigma
- Iatrogenic harm: unnecessary medical procedures or medications when dissociative symptoms are misattributed to neurological conditions
Prognosis
The natural course of DDD is variable. Some key prognostic features:
Duration: Symptoms lasting less than 1 year have better prognosis. When symptoms persist beyond 1 year, the disorder often becomes chronic.
Onset: Acute onset associated with identifiable stressor has better prognosis than insidious onset.
Comorbidity: Presence of multiple comorbid psychiatric conditions is associated with worse prognosis.
Treatment response: Approximately one-third of patients experience significant improvement with treatment, one-third have mild to moderate improvement, and one-third have persistent severe symptoms despite treatment.
Long-term outcome: Complete remission is uncommon once the disorder becomes chronic. However, many patients learn to function despite symptoms through therapy and coping strategies. Symptoms often wax and wane, with periods of exacerbation during stress.
Favorable prognostic factors: younger age at onset, acute onset, absence of comorbid personality disorders, engagement in psychotherapy, good social support, absence of ongoing trauma or severe life stress.
Overall, while DDD is often chronic and can significantly impact quality of life, most patients do not deteriorate over time, and many achieve functional improvement even if symptoms do not fully remit.
Practice questions
1. A 22-year-old woman presents to the clinic reporting that for the past 8 months she has felt "disconnected" from herself, as if she is "watching herself from outside her body." She describes feeling emotionally numb and says the world around her seems "foggy and unreal." She is distressed by these symptoms and has difficulty concentrating at work. She denies any substance use. When asked if she believes these experiences are real, she replies, "No, I know logically that I'm still me and the world is real, but it just doesn't feel that way." Mental status examination shows an anxious but fully oriented patient with organized thought processes and no hallucinations or delusions. What is the most likely diagnosis?
2. A 19-year-old college student is brought to the emergency department by friends after expressing suicidal thoughts. He reports that for the past year, he has felt as if he is "living in a dream" and that nothing seems real. He describes feeling detached from his emotions and has difficulty connecting with friends. He admits to daily marijuana use for the past 2 years. On examination, he appears depressed and admits he has been "hearing voices" telling him he is "not real" for the past 3 months. When asked if he believes the voices are real, he states, "Yes, they are telling me the truth—I'm disappearing." What is the most appropriate next step in diagnosis?
3. A 28-year-old woman with a 3-year history of depersonalization-derealization disorder returns for follow-up. She has completed 6 months of cognitive behavioral therapy with modest improvement in anxiety but minimal change in her persistent feelings of detachment from her body and surroundings. She has no history of substance use and no current depression. Her therapist has optimized grounding techniques and cognitive strategies. What is the most appropriate next pharmacological intervention?
Frequently asked questions
What causes depersonalization-derealization disorder?
DDD is caused by a combination of severe stress, trauma (especially childhood emotional abuse or neglect), anxiety disorders, and substance use (particularly cannabis and hallucinogens). Neurobiologically, it involves dysfunction in brain regions that process emotions and self-awareness, with excessive inhibition of the limbic system by the prefrontal cortex. The disorder is thought to be a protective dissociative response when emotional arousal exceeds an individual's coping capacity.
What are the first symptoms of depersonalization-derealization disorder?
The first symptoms typically include feeling detached or disconnected from oneself (like observing yourself from outside your body) or feeling that surroundings are unreal, dreamlike, or foggy. Patients often describe emotional numbness, feeling like a robot, or as if they are living in a movie. Importantly, they maintain insight and know these feelings are not real, which distinguishes DDD from psychosis. Symptoms usually begin in adolescence or early adulthood, often triggered by stress or trauma.
How is depersonalization-derealization disorder diagnosed?
DDD is diagnosed clinically based on history and mental status examination. The key diagnostic features are persistent or recurrent feelings of detachment from self or surroundings, intact reality testing (patient knows the experiences are distortions), and significant distress or functional impairment. Medical causes must be ruled out through thyroid tests and toxicology screening. Brain imaging may be needed if neurological symptoms are present. There is no specific blood test or scan for DDD.
Is depersonalization-derealization disorder curable?
DDD is often chronic and complete cure is uncommon, especially when symptoms have persisted beyond one year. However, significant improvement is possible with treatment. Approximately one-third of patients experience substantial improvement with cognitive behavioral therapy and treatment of comorbid anxiety or depression. Many patients learn effective coping strategies and achieve functional improvement even if symptoms do not completely resolve. Early treatment, acute onset, and absence of multiple comorbidities predict better outcomes.
Depersonalization-derealization disorder vs schizophrenia—what is the difference?
The critical difference is reality testing. In DDD, patients maintain insight and know their feelings of detachment or unreality are distortions—they recognize the experiences are subjective, not actual reality. In schizophrenia and other psychotic disorders, reality testing is impaired—patients believe their perceptual disturbances, hallucinations, or delusions are real. Additionally, schizophrenia presents with hallucinations, delusions, and thought disorder, which are not features of DDD. Both may involve feeling detached, but the preserved insight in DDD is the key distinguishing feature.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: F48.1
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.